Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Platinum + Bevacizumab in HER2+, HRD- High-Risk Ovarian Cancer
NCT07311577Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in ovarian cancer, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Started Jan 2026; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07311577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311577.